Study of HTX-019 in healthy volunteers

Trial Profile

Study of HTX-019 in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Aprepitant (Primary) ; Fosaprepitant
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions
  • Sponsors Heron Therapeutics
  • Most Recent Events

    • 12 Jan 2017 According to a Heron Therapeutics media release, the company has submitted a New Drug Application (NDA) for HTX-019 (CINVANTI) for the prevention of chemotherapy induced nausea and vomiting. The filing includes data from this trial.
    • 23 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top